tion includes detection of the cpsA gene common to all pneumococcal serotypes, which was used as the internal control. The PCR amplification protocol and fluorescent fragment size analysis were as described in the published assay (1), except for the number of amplification cycles, which was increased to 35.
Among the 98 PF samples positive for S. pneumoniae DNA, the cpsA gene (internal control) was detected in 74 samples and all of them were correctly serotyped with the FAF-mPCR. Among the remaining 24 samples, no cpsA amplification was detected after 35 cycles of amplification; of these 24 samples, 23 (95.8%) had C T values of Ͼ30 in the previous diagnostic real-time PCR assay and only one sample had a C T value of Յ30 (this sample had been serotyped as 9V/A/N/L with the multiplex real-time PCR). The congruence between FAF-mPCR and multiplex real-time PCR results based on the Wallace coefficient was 0.998 (0.995 to 1.000) in those samples with C T values of Յ30. The results of FAF-mPCR and multiplex real-time PCR were in complete agreement for the 24 capsular types detected by both methods in the 74 samples that had positive detection of cpsA. Moreover, two additional capsular types were identified by FAM-mPCR in two samples in which the capsular type had not been identified with the multiplex real-time PCR assay (Table 1 ).
In conclusion, these results indicate that FAF-mPCR could be used for pneumococcal capsular typing directly on clinical samples with high bacterial loads (C T value for ply by real-time PCR, Յ30), even in culture-negative patients. 
